ia, Bulgaria, Australia, England, the USA). The process started with review of the clinical questions that the
Writing Committee proposed to address, which were
subsequently adjusted, and which formed the basis of
the guideline development. The Ô¨Årst preliminary version
of the guideline was reviewed by the IWGDF, ESVS, and
members of the SVS Document Oversight Committee.

The revised text was then reviewed by the external experts and patient representatives, and subsequently a
new version was